Ferumoxytol增强磁共振成像评估心肌梗死后炎症
研究纳入31例急性心肌梗死患者,随访3个月,采用USPIO增强T2* mapping MRI评估细胞炎症与组织水肿的时间变化。结果显示USPIO增强在单次给药后24小时内可检测到,重复给药后梗死区摄取在第2-3天达峰,而T2定义的水肿在第3-9天达峰并持续至3个月。结论认为USPIO增强MRI可在急性心梗后2周内检测心肌巨噬细胞活性。
要点
- USPIO增强MRI可在急性心梗后2周内检测心肌巨噬细胞活性。
- 重复给药后梗死区USPIO摄取第2-3天达峰,至第10-16天仍高于远端心肌。
- T2定义的心肌水肿第3-9天达峰,梗死区在整个3个月随访期持续增高。
核心结论
- USPIO增强MRI可在急性心肌梗死后2周内检测心肌巨噬细胞活性,该细胞炎症模式与T2 mapping检测的更持久心肌水肿不同并提供互补信息。
研究设计与样本
- 研究纳入31例急性心肌梗死患者,随访3个月,重复进行T2和USPIO增强T2* mapping MRI,将感兴趣区分为梗死区、梗死周围区和远端心肌区并与对照组织比较。
- 组织学证实铁与巨噬细胞在梗死心肌内共定位,而在非梗死心肌内无共定位。
主要发现
- 单次给药后,USPIO增强在心肌中可检测至24小时(p<0.0001)。
- 重复给药后,梗死区USPIO摄取在第2-3天达峰,至第10-16天梗死区USPIO摄取仍高于远端心肌(p<0.05)。
- T2定义的心肌水肿在第3-9天达峰,梗死区在整个3个月随访期内持续增高(p<0.01)。
临床怎么用
- 该成像技术有望作为无创评估和监测心肌细胞炎症的方法,潜在应用于诊断、风险分层和评估新型抗炎治疗干预。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Macrophages play a central role in the cellular inflammatory response to myocardial infarction (MI) and predict subsequent clinical outcomes. We aimed to assess temporal changes in cellular inflammation and tissue oedema in patients with acute MI using ultrasmallsuperparamagnetic particles of iron oxide (USPIO)-enhanced MRI. METHODS: Thirty-one patients were recruited following acute MI and followed up for 3 months with repeated T2 and USPIO-enhanced T2*-mapping MRI. Regions of interest were categorised into infarct, peri-infarct and remote myocardial zones, and compared with control tissues. RESULTS: Following a single dose, USPIO enhancement was detected in the myocardium until 24 hours (p<0.0001). Histology confirmed colocalisation of iron and macrophages within the infarcted, but not the non-infarcted, myocardium. Following repeated doses, USPIO uptake in the infarct zone peaked at days 2-3, and greater USPIO uptake was detected in the infarct zone compared with remote myocardium until days 10-16 (p<0.05). In contrast, T2-defined myocardial oedema peaked at days 3-9 and remained increased in the infarct zone throughout the 3-month follow-up period (p<0.01). CONCLUSION: Myocardial macrophage activity can be detected using USPIO-enhanced MRI in the first 2 weeks following acute MI. This observed pattern of cellular inflammation is distinct, and provides complementary information to the more prolonged myocardial oedema detectable using T2 mapping. This imaging technique holds promise as a non-invasive method of assessing and monitoring myocardial cellular inflammation with potential application to diagnosis, risk stratification and assessment of novel anti-inflammatory therapeutic interventions. TRIAL REGISTRATION NUMBER: Trial registration number: 14663. Registered on UK Clinical Research Network (http://public.ukcrn.org.uk) and also ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT02319278?term=DECIFER&rank=2).
引用
- Stirrat CG, Alam SR, MacGillivray TJ, et al. Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction. Heart. 2017. PMID: 28642288. doi:10.1136/heartjnl-2016-311018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。